中国临床药理学杂志2024，Vol.40Issue(17)：2469-2473,5.DOI:10.13699/j.cnki.1001-6821.2024.17.003
卡瑞利珠单抗用于Ⅲa期NSCLC患者术前新辅助化疗的临床研究
Clinical trial of carrelizumab for preoperative neoadjuvant chemotherapy in patients with stage Ⅲa NSCLC
闫红江 1李铁志 1焦晓丹 2高少林1
作者信息
- 1. 河北医科大学第二医院,胸外科,河北石家庄 050000
- 2. 河北医科大学第二医院,呼吸与危重症,河北石家庄 050000
- 折叠
摘要
Abstract
Objective To observe the clinical effect and safety of camrelizumab combined with albumin-bound paclitaxel and cisplatin in preoperative neoadjuvant chemotherapy for patients with stage Ⅲa non-small cell lung cancer(NSCLC).Methods Patients with stage Ⅲ a NSCLC were divided into the treatment group and the control group.The control group was treated with intravenous infusion of 130 mg·m-2 of paclitaxel injection on day 1 and day 8,and intravenous infusion of 75 mg·m-2 of cisplatin injection on day 1.In addition to the treatment of control group,the treatment group was treated with intravenous infusion of 200 mg of camrelizumab injection on day 1.Both groups were given 2 cycles of treatment.Clinical efficacy,tumor markers,tumor metastasis markers,T lymphocyte subsets,and safety were compared between the two groups.Results After treatment,the objective remission rate(ORR)of the treatment group and the control group was 69.64％(39 cases/56 cases)and 38.98％(23 cases/59 cases),respectively;the disease control rate(DCR)was 89.29％(50 cases/56 cases)and 72.88％(43 cases/59 cases),respectively;cytokeratin-19-fragment(Cyfra21-1)levels were(3.47±0.86)and(4.01±1.24)ng·mL-1;carcinoembryonic antigen(CEA)levels were(4.55±0.93)and(5.26±1.04)ng·mL-1;neuron-specific enolase(NSE)levels were(16.38±2.51)and(19.02±2.95)ng·mL-1;basic fibroblast growth factor(bFGF)levels were(15.82±2.34)and(18.64±2.59)μg·L-1;carbohydrate antigen 15-3(CA15-3)levels were(22.54±3.10)and(29.41±3.82)ng·mL-1;CD4+/CD8+were 1.42±0.51 and 1.30±0.32.The above indexes were significantly different between the control group and the treatment group(all P＜0.05).The adverse drug reactions in the treatment group and the control group were mainly neutropenia,thrombocytopenia,alopecia,gastrointestinal reaction and radiation pneumonia.There were no significant difference in the incidence of adverse drug reactions between the two groups(all P＞0.05).Conclusion Camrelizumab combined with albumin-bound paclitaxel and cisplatin is effective in the treatment of patients with stage Ⅲa NSCLC.关键词
注射用卡瑞利珠单抗/注射用紫杉醇/注射用顺铂/非小细胞肺癌/术前新辅助化疗/疗效Key words
carrelizumab injection/paclitaxel injection/cisplatin injection/non-small cell lung cancer/preoperative neoadjuvant chemotherapy/curative effect分类
医药卫生引用本文复制引用
闫红江,李铁志,焦晓丹,高少林..卡瑞利珠单抗用于Ⅲa期NSCLC患者术前新辅助化疗的临床研究[J].中国临床药理学杂志,2024,40(17):2469-2473,5.
